The total number of records retrieved from this search are 54. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_325	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result98% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_329	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration2.5 MOI	In-vitro result98% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_333	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration5 MOI	In-vitro result98% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_337	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result99% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_341	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration20 MOI	In-vitro result100% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_380	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cholangiocarcinoma cell line	Cell lineKMCH-1	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayDojindo cell counting kit	In-vitro virus concentration0.01 MOI	In-vitro result13% cancer cell viability on 7 day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26584530
IDOV_383	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cholangiocarcinoma cell line	Cell lineKMCH-1	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayDojindo cell counting kit	In-vitro virus concentration0.1 MOI	In-vitro result13% cancer cell viability on 7 day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26584530
IDOV_386	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cholangiocarcinoma cell line	Cell lineKMCH-1	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayDojindo cell counting kit	In-vitro virus concentration1 MOI	In-vitro result13% cancer cell viability on 7 day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26584530
IDOV_389	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cholangiocarcinoma cell line	Cell lineKMCH-1	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayDojindo cell counting kit	In-vitro virus concentration5 MOI	In-vitro result13% cancer cell viability on 7 day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26584530
IDOV_1607	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineH-1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result30% cell are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1620	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineH-1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result25% cells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1633	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineH-1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result25% cells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1646	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineH-1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration20 MOI	In-vitro result15% cells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_2785	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2786	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2787	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2788	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration5 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2789	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultAll cell was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2790	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2791	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2792	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result80% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2793	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result80% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2794	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_3332	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3333	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3334	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3335	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3336	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3337	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3338	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3339	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result20% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3340	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result100% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3341	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3342	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3343	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3344	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3345	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3346	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3347	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3348	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3349	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3631	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3632	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result5% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3645	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3646	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3659	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3660	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_4326	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman nonsmall cell lung cancer	Cell lineH-1299	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result96.3 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4947	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4948	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4949	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4950	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineH-1299	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_5596	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung carcinoma cell line	Cell lineH-1299	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration26 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5832	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineH-1299	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration26 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578